EMAIL THIS PAGE TO A FRIEND

Biochimica et biophysica acta

Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts.


PMID 25283819

Abstract

The cardiotoxicity induced by the anti-cancer doxorubicin involves increased oxidative stress, disruption of calcium homeostasis and activation of cardiomyocyte death. Nevertheless, antioxidants and caspase inhibitors often show little efficacy in preventing cell death. We hypothesize that a caspase-independent cell death mechanism with the release of the apoptosis-inducing factor from mitochondria is involved in doxorubicin toxicity. To test the hypothesis, H9c2 cardiomyoblasts were used as model for cardiac cells. Our results demonstrate that z-VAD-fmk, a pan-caspase inhibitor, does not prevent doxorubicin toxicity in this cell line. Doxorubicin treatment results in AIF translocation to the nuclei, as confirmed by Western Blotting of cell fractions and confocal microscopy. Also, doxorubicin treatment of H9c2 cardiomyoblasts resulted in the appearance of 50kbp DNA fragments, a hallmark of apoptosis-inducing factor nuclear effects. Apoptosis-inducing factor knockdown using a small-interfering RNA approach in H9c2 cells resulted in a reduction of doxorubicin toxicity, including decreased p53 activation and poly-ADP-ribose-polymerase cleavage. Among the proteases that could be responsible for apoptosis-inducing factor cleavage, doxorubicin decreased calpain activity but increased cathepsin B activation, with inhibition of the latter partly decreasing doxorubicin toxicity. Altogether, the results support that apoptosis-inducing factor release is involved in doxorubicin-induced H9c2 cell death, which explains the limited ability of caspase inhibitors to prevent toxicity.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

86760
1,1,2,2-Tetrabromoethane, purum p.a., for separation (of mineral compounds), ≥98.0% (GC)
C2H2Br4
185574
1,1,2,2-Tetrabromoethane, 98%
C2H2Br4
32900
Benalaxyl-M, PESTANAL®, analytical standard
C20H23NO3
B6768
Boric acid, BioReagent, for molecular biology, suitable for cell culture, suitable for plant cell culture, ≥99.5%
H3BO3
B7901
Boric acid, for electrophoresis, ≥99.5%
H3BO3
B2645
Boric acid, tablet, 1 g boric acid per tablet
H3BO3
202878
Boric acid, 99.999% trace metals basis
H3BO3
339067
Boric acid, 99.97% trace metals basis
H3BO3
B7660
Boric acid, BioXtra, ≥99.5%
H3BO3
B0394
Boric acid, ACS reagent, ≥99.5%
H3BO3
B0252
Boric acid, ReagentPlus®, ≥99.5%
H3BO3
15663
Boric acid, BioUltra, for molecular biology, ≥99.5% (T)
H3BO3
31146
Boric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., buffer substance, ≥99.8%
H3BO3
11607
Boric acid, puriss., meets analytical specification of Ph. Eur., BP, NF, 99.5-100.5%, powder
H3BO3
426148
Boric acid-11B, ≥99 atom % 11B
H311BO3
D2975000
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
C27H29NO11 · HCl
1225703
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
C27H29NO11 · HCl
A2559
N-Acetyl-Asp-Glu-Val-Asp p-nitroanilide, ≥97% (HPLC), powder
C26H34N6O13
424455
Resorufin, Dye content 95 %
C12H7NO3
73144
Resorufin, 95%
C12H7NO3
230162
Sulforhodamine B, Dye content 75 %
C27H29N2NaO7S2
S9012
Sulforhodamine B sodium salt, Technical grade
C27H29N2NaO7S2
S1402
Sulforhodamine B sodium salt, powder, BioReagent, suitable for cell culture
C27H29N2NaO7S2